1. Herbort CP Jr, Takeuchi M, Papasavvas I, Tugal-Tutkun I, Hedayatfar A, Usui Y, Ozdal PC, Urzua CA. Optical Coherence Tomography Angiography (OCT-A) in Uveitis: A Literature Review and a Reassessment of Its Real Role. Diagnostics (Basel). 2023 Feb 7;13(4):601.
2. Cifuentes-González C, Rojas-Carabali W, Pérez ÁO, Carvalho É, Valenzuela F, Miguel-Escuder L, Ormaechea MS, Heredia M, Baquero-Ospina P, Adan A, Curi A, Schlaen A, Urzua CA, Couto C, Arellanes L, de-la-Torre A. Risk factors for recurrences and visual impairment in patients with ocular toxoplasmosis: A systematic review and meta-analysis. PLoS One. 2023 Apr 3;18(4):e0283845.
3. Molina-Moya MA, Gómez-Pérez L, Repetto-Lisboa P, Ramos-Negrete N, Cuitino L, Vega-Tapia F, Urzua CA, Sidgman AJ. Salud mental y adherencia al tratamiento en pacientes con uveítis (Mental health and treatment adherence in patients with uveítis). Iris. 2023;2(1):2-8
1. Tasiopoulou A, Urzua CA, Lightman S. Successful treatment of cytomegalovirus retinitis with oral/intravitreal antivirals in HIV-negative patients with lymphoma. Eye (Lond). 2022 Oct 3. Epub ahead of print.
2. Urzua CA, Herbort CP Jr, Takeuchi M, Schlaen A, Concha-Del-Rio LE, Usui Y, Cuitino L, Papasavvas I. Vogt-Koyanagi-Harada disease: the step-by- step approach to a better understanding of clinicopathology, immunopathology, diagnosis, and management: a brief review. Ophthalmic Inflamm Infect. 2022;12(1):17.
3. Neri P, Herbort CP Jr, Hedayatfar A, Tugal-Tutkun I, Cimino L, Urzua CA, Papasavvas I, Takeuchi M, Lages V. "White dot syndromes", an inappropriate and outdated misnomer. Int Ophthalmol. 2022;42(1):1-6.
4. Vega-Tapia F, Elizalde N, Valenzuela RA, Urzua CA, Cuitiño L. miRNAs: una nueva mirada de la enfermedad de Vogt-Koyanagi-Harada. Rev Hosp Clín Univ Chile 2022;33:108 - 19
1. Herbort CP Jr, Tugal-Tutkun I, Abu-El-Asrar A, Gupta A, Takeuchi M, Fardeau C, Hedayatfar A, Urzua C, Papasavvas I. Precise, simplified diagnostic criteria and optimised management of initial-onset Vogt-Koyanagi-Harada disease: an updated review. Eye (Lond). 2021;36(1):29-43
2. Vega-Tapia F, Bustamante M, Valenzuela RA, Urzua CA, Cuitino L. miRNA Landscape in Pathogenesis and Treatment of Vogt–Koyanagi–Harada Disease. Front Cell Dev Biol 2021; 9:658514.
3. Urzua CA, Knickelbein J, Cuitino L, Moreno U, Anguita R, Velasquez V, Concha-Del-Rio LE, Morales S, Villarroel FA, Sen HN, Arellanes-Garcia L. Association of retinal detachment with age 50 years or younger at onset in patients with Acute Retinal Necrosis. Graefes Arch Clin Exp Ophthalmol 2021; 259(10):2905-2911
1. Urzua CA, Herbort C Jr, Valenzuela RA, Abu El-Asrar AM, Arellanes-Garcia L, Schlaen A, Yamamoto J, Pavesio C. Initial-onset acute and chronic recurrent stages are two distinctive courses of Vogt- Koyanagi-Harada disease. J Ophthalmic Inflamm Infect 2020;10 (1):23.
2. Valenzuela RA, Flores I, Pujol M, Llanos C, Carreño E, Rada G, Herbort CP Jr, Cuitino L, Urzua CA. Definition of Uveitis Refractory to Treatment: A Systematic Review in the Absence of a Consensus.Ocul Immunol Inflamm 2020; Sep 4:1-6.[Online ahead of print].
3. Valenzuela RA, Flores I, Urrutia B, Fuentes F, Sabat PE, Llanos C, Cuitino L, Urzua CA. New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview. Front Pharmacol 2020;11:655.
4. Sabat PE, Anguita R, Saez V, Morales S, Urzúa CA, Villarroel FA, Velásquez V. Diabetes Mellitus- associated uveitis: Clinical features in a Chilean Series. Ocul Immunol Inflamm 2020;28:571-574.
1. Urzua CA, Chen P, Chaigne-Delalande B, Liu B, Anguita R, Guerrero J, Sabat P, Velasquez V, Sen HN, Lee RWJ, Goecke A. Glucocorticoid receptor α and MKP-1 as candidate biomarkers for treatment response and disease activity in Vogt-Koyanagi- Harada Disease. Am J Ophthalmol 2019;207:319-325.
2. Herrada AA, Escobedo N, Iruretagoyena M, Valenzuela RA, Burgos PI, Cuitino L, Llanos C. Innate Immune Cells' Contribution to Systemic Lupus Erythematosus. Front Immunol. 2019;10:772.